Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
NCT07380165 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-02-24
Summary
This expanded access program provides investigational levacetylleucine to patients with Ataxia-Telangiectasia who are not eligible for clinical trials and have no satisfactory alternative therapies.
Conditions
- Ataxia-Telangiectasia (A-T)
Interventions
- DRUG
-
Levacetylleucine
1 gram levacetylleucine as granules in unit-dose packet. Investigational drug is administered as oral suspension, up to three times per day, based on body weight.
Sponsors & Collaborators
-
IntraBio Inc
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
NCT03461289 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03537807 ·Status: NO_LONGER_AVAILABLE
-
Intermediate Expanded Access Protocol CNMAu8.EAP04
NCT06408727 ·Status: TEMPORARILY_NOT_AVAILABLE
-
RT001 in Amyotrophic Lateral Sclerosis
NCT04762589 ·Status: COMPLETED ·Phase: PHASE2
-
AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications.
NCT04240314 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
NCT02865109 ·Status: NO_LONGER_AVAILABLE
-
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
NCT04851873 ·Status: COMPLETED ·Phase: PHASE3
-
Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies
NCT03837184 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy
NCT02376816 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
NCT04042025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT05230459 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
NCT05445323 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
NCT01239758 ·Status: TERMINATED ·Phase: PHASE2
-
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
NCT02592941 ·Status: APPROVED_FOR_MARKETING
-
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
NCT07250737 ·Status: AVAILABLE
-
Long-Term Follow-up Study for Patients From AVXS-101-CL-101
NCT03421977 ·Status: ACTIVE_NOT_RECRUITING
-
(-)- Epicatechin Becker Muscular Dystrophy
NCT03236662 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Oxaloacetate in ALS
NCT04204889 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy
NCT01369901 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study for the Treatment for CLN7 Disease
NCT04737460 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
NCT02122952 ·Status: COMPLETED ·Phase: PHASE1
-
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
NCT03306277 ·Status: COMPLETED ·Phase: PHASE3
-
Adult SMA Research and Clinical Hub
NCT06978985 ·Status: RECRUITING
-
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
NCT04887311 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119 ·Status: RECRUITING ·Phase: PHASE1